Evidence map›Paper›PMID 38902561›Full record

ArticleJournal of neuro-oncology2024

Dosimetric evaluation and treatment planning considerations for GammaTile permanent brain implants - a pilot, institutional experience.

Shunqing Zhang, Krishnan Patel, Kathryn Dusenbery, Abdullah Alshreef, David Sterling, Lindsey Sloan, Margaret Reynolds, Clark C Chen, Clara Ferreira

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shunqing ZhangNorthwestern Medical Group, Chicago, IL, USA.
Krishnan PatelNational Institutes of Health, Bethesda, MD, USA.
Kathryn DusenberyUniversity of Minnesota, Minneapolis, MN, USA.
Abdullah AlshreefUniversity of Minnesota, Minneapolis, MN, USA.
David SterlingUniversity of Minnesota, Minneapolis, MN, USA.
Lindsey SloanUniversity of Minnesota, Minneapolis, MN, USA.
Margaret ReynoldsUniversity of Minnesota, Minneapolis, MN, USA.
Clark C ChenBrown University, Providence, RI, USA.
Clara FerreiraUniversity of Minnesota, Minneapolis, MN, USA. cferreir@umn.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGammaTile® (GT) is a brachytherapy platform that received Federal Drug Administration (FDA) approval as brain tumor therapy in late 2018. Here, we reviewed our institutional experience with GT as treatment for recurrent glioblastomas and characterized dosimetric parameter and associated clinical outcome. METHODS AND MATERIALS: A total of 20 consecutive patients with 21 (n = 21) diagnosis of recurrent glioblastoma underwent resection followed by intraoperative GT implant between 01/2019 and 12/2020. Data on gross tumor volume (GTV), number of GT units implanted, dose coverage for the high-risk clinical target volume (HR-CTV), measured by D

resultsThe median D

conclusionsOur pilot, institutional experience provides clinical outcome, dosimetric considerations, and offer technical guidance in the clinical implementation of GT brachytherapy.

Indexed as

BrachytherapyBrain NeoplasmsGlioblastomaRadiotherapy DosageRadiotherapy Planning, Computer-AssistedAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalOrgans at RiskPilot ProjectsPrognosisBrachytherapyDosimetryGammaTileGlioblastomaRadiotherapyTreatment planning

Identifiers

PMID38902561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.